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INTRODUCTION
Neurofibromatosis type 1 (NF1) is one of the most com-
mon inherited disorders, with an estimated incidence of 1
per 3,500 births. NF1 is caused by mutations in the NF1 gene.
The NF1 gene maps to 17q11.2, contains 57 exons spanning
approximately 280 kb of genomic DNA, and encodes neu-
rofibromin (1, 2). Neurofibromin, which consists of 2,818
amino acids, is widely expressed in many tissues and acts as
a Ras GTPase activating protein (GAP) (3). Two functional
regions of neurofibromin have been identified and well-
defined, a central GAP related domain (GRD) encoded by
exons 20-27 (4, 5) and several cAMP-dependent protein
kinase recognition sites encoded by exons 11-17 (6). The
NF1 gene exhibits one of the highest mutation rates of any
human disorder. To date, more than 640 different NF1 muta-
tions have been found and listed in the Human Gene Muta-
tion Database (HGMD). The majority of them lead to a trun-
cated protein product. 
NF1 is clinically characterized by cafe-au-lait (CAL) spots,
neurofibromas, freckling of the axillary or inguinal region,
Lisch nodules, optic nerve glioma, and bone dysplasias (7).
These features are present in more than 90% of patients at
puberty. Further manifestations such as deeply situated and
arbitrarily located neurofibromas, plexiform neurofibromas,
macrocephaly, short stature, learning difficulties, scoliosis,
and pseudarthrosis, as well as certain malignancies, occur less
frequently among patients with NF1 (8). NF1 is notable for
its extreme phenotypic variability both within and between
families. In addition to multiple allelism of the NF1 locus,
the influence of modifying gene(s) and the impact of stochas-
tic events have been suggested as causes of this variability
(9, 10). However, evidence supporting these hypotheses has
not been reported.
A comprehensive analysis of the mutational spectrum might
help to elucidate the molecular basis of different NF1 muta-
tions. In Korea, only three cases of NF1 have been previously
reported (11, 12). In order to assess the NF1 mutational spec-
trum in Korean NF1 patients, we performed phenotypic
characterization and mutation analysis in 23 unrelated cases.
Here, we report the spectrum of NF1 mutations in Korean
NF1 patients, and discuss a genotype-phenotype correlation
analysis. 
MATERIALS AND METHODS
Patients
Twenty-three NF1 patients of 9 familial and 14 sporadic
cases were screened for mutations of the NF1 gene. All sub-
jects were diagnosed to have NF1 based on standard diag-
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Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant
disorders in humans. NF1 is caused by mutations in the NF1 gene which consists
of 57 exons and encodes a GTPase activating protein (GAP), neurofibromin. To
date, more than 640 different NF1 mutations have been identified and registered
in the Human Gene Mutation Database (HGMD). In order to assess the NF1 muta-
tional spectrum in Korean NF1 patients, we screened 23 unrelated Korean NF1
patients for mutations in the coding region and splice sites of the NF1 gene. We
have identified 21 distinct NF1 mutations in 22 patients. The mutations included
10 single base substitutions (3 missense and 7 nonsense), 10 splice site mutations,
and 1 single base deletion. Eight mutations have been previously identified and
thirteen mutations were novel. The mutations are evenly distributed across exon 3
through intron 47 of the NF1 gene and no mutational hot spots were found. This
analysis revealed a wide spectrum of NF1 mutations in Korean patients. A geno-
type-phenotype correlation analysis suggests that there is no clear relationship bet-
ween specific NF1 mutations and clinical features of the disease. 
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nostic criteria (7) at the Genetics Clinic in Ajou University
Medical Center between December 2003 and March 2005. 
Phenotypic characterization and mutation analysis
Phenotypic characterization of all subjects was done at the
Genetics Clinic in Ajou University Medical Center and is
summarized in Table 1. Mutation screening was performed
in the Medical Genetics Laboratory, Department of Genetics,
University of Alabama at Birmingham, U.S.A. Based on the
screening data of the NF1 patients, we performed a detailed
mutation analysis of the NF1 gene and further analysis of
genotype-phenotype correlations. 
Mutation screening was performed as described previously
(13). Briefly, genomic DNA was prepared from blood sam-
ples of the patients and total RNA was extracted from lym-
phocytes isolated from the blood samples and amplified in
culture. Microsatellite polymorphism markers were analyzed
as a first approach to determine whether 2 copies of the NF1
gene were present. If no heterozygous signal was observed
for any of these markers, FISH analysis was performed using
PAC clones 22 (926B9; 5′ NF1) and 13 (1002G3; 3′ NF1)
to confirm or rule out a total gene deletion. Thereafter, genom-
ic DNA-PCR and RT-PCR were performed to screen splice
Pt.
No.
S/F Clinical features
Genotypic characteristics
Mutation
location
Nucleotide 
change
Amino acid
change
Mutation type/
effect 
Reference (No.) Age
1 F 45 yr CALs, CNf, SCNf, F Exon 3 c.236delT - Deletion/ This report
Frame shift
2 S 4 yr CALs, SCNf Exon 4 c.532G>T E178X Nonsense/ This report
Truncating
3 F 35 yr CALs, SCNf, F Intron 8 IVS8+1G>A - Splicing error Ars et al. (20)
4 F 40 yr CALs, multiple SCNf, F Exon 10 c.1381C>T R461X Nonsense/ Fahsold et al. (17)
Truncating
5 S 6 yr CALs, PNf, LN Intron 10 c.1642-449A>G - Splicing error This report
6 S 6.9 yr CALs, CNf, F Exon 12 c.1733T>C L578P Missense/ This report
Regular size
7 S 22 yr CALs, PNf (leg) LN, F Intron 13 c.2033_2034insC Splicing error This report
8S 6  m o CALs Intron 14 c.2252-33_-8del26 - Spicing error This report
9S 2  m o CALs Exon 16 c.2446C>T R816X Nonsense/ Maynard et al. (26) 
Truncating
10 F 14 yr CALs, F, Facial asymetry Intron 16 c.2851-2A>C - Splicing error This report
11 S 3 yr CALs Intron 21 IVS21+2-3insT - Splicing error This report
12 F 23 yr CALs, CNf, SCNf Exon 22 c.3827G>A R1276Q Missense/ Fahsold et al. (17)
Regular size
13 F 20 yr CALs, CNf, SCNf, LN, F Intron 24 c.4269+1_4269 - Splicing error This report
+12del12bp
14 S 6.5 yr CALs, PNf Exon 27 c.4537C>T R1513X Nonsense/ Side et al. (21)
Truncating
15 S 10.7 yr CALs, PNf (left leg) Exon 27 c.4537C>T R1513X Nonsense/ Side et al. (21) 
SCNf, LN, F Truncating
16 S 32 yr CALs, CNf, SCNf, PNf (leg) Exon 28 c.4861G>A,  V1621R Missense/ This report
c.4862T>G Regular size
17 S 14.5 yr CALs, CNf, SCNf Intron 30 c.5749+4_ - Splicing error This report
+7delAGTA
18 S 16 yr CALs, CNf, SCNf, axillary F Intron 31 c.5750-?_5943+?del - Splicing error This report
19 F 17 yr CALs, CNf, SCNf F Exon 36 c.6709C>T R2237X Nonsense/ Fahsold et al. (17)
Truncating
20 F 24 yr CALs, PNf, CNf, SCNf, S Exon 37 c.6792C>G Y2264X Nonsense/ Messiaen et al. (22)
Exon skipping
21 S 4 yr CALs, seizures, microcephaly Exon 37 c.6792C>A Y2264X Nonsense/ Robinson et al. (27) 
Exon skipping
22 F 2 yr CALs, PA, Brain glioma Intron 47 c.61-?_8315-?del - Splicing error This report
23 S 1.6 yr CALs No pathogenic mutation has been identified
Table 1. Summary of clinical features and genotypic characteristics of 23 Korean patients with NF1
Legend: S/F, Sporadic/Familial; CALs, Cafe-au-Lait Spots; CNf, Cutaneous Neurofibromas; SCNf, Subcutaneous Neurofibromas; PNf, Plexiform Neu-
rofibromas; LN, Lisch Nodules; F, Freckling; S, Scoliosis; PA, Pseudarthrosis. 
Nucleotide numbering is based on the NF1 cDNA sequence (GenBank accession No. M82814) and genomic DNA sequence (GenBank accession
No. AY796305). NF1 Mutations in Korean Neurofibromatosis 1 Patients 109
site mutations and coding region mutations of the NF1 gene,
respectively. Sequencing was performed using dye-primer
chemistry on an ABI3100 capillary sequencer (Applied Bio-
systems, Foster City, CA, U.S.A.). 
RESULTS
Description of mutations
The patients were analyzed using genomic PCR-directed
sequencing, microsatellite polymorphism analysis, FISH anal-
ysis, and RT-PCR. Several other methods, including hetero-
duplex analysis (HA), protein truncation test (PTT), and
denaturing high performance liquid chromatography (DH-
PLC), have been used for analysis of NF1 mutations (13, 14)
and are useful for high-throughput detection of mutations.
However, we used PCR-directed genomic sequencing as our
primary technique to detect mutations because it is very accu-
rate and directly identifies changes in gene sequence.
Twenty-three unrelated patients who were clinically diag-
nosed with NF1 were screened for mutations in the coding
region (57 exons) and splice sites of the NF1 gene. Muta-
tions in NF1 were detected in 22 of 23 patients (96%). Muta-
tion analysis revealed a wide spectrum of NF1 mutations in
these patients (Table 1). Twenty-one different mutations
were identified, which included 10 single base substitutions
(3 missense and 7 nonsense), 10 splice site mutations, and 1
single base deletion. Eight mutations (38%) have been pre-
viously reported and thirteen mutations (62%) were novel.
Only 2 patients shared the same mutation, c.4537C>T, and
20 patients had unique mutations, indicating that no muta-
tional ‘‘hot spots’’ exist in Korean NF1 patients. 
The mutations were evenly distributed across exon 3 to
intron 47 of the NF1 gene (Fig. 1). The previously charac-
terized mutations detected in this study were: IVS8+1G>A
in intron 8, c.1381C>T (R461X) in exon 10, c.2446C>T
(R816X) in exon 16, c.3827G>A (R1276Q) in exon 22,
c.4537C>T (R1513X) in exon 27, c.6709C>T (R2237X) in
exon 36, c.6792C>G (Y2264X) in exon 37, and c.6792C>A
(Y2264X) in exon 37. The newly identified mutations were:
c.236delT in exon 3, c.532G>T (E178X) in exon 4, c.1642-
449A>G in intron 10, c.1733T>C (L578P) in exon 12,
c.2033_2034insC in intron 13, c.2252-33_-8del26 in intron
14, c.2851-2A>C in intron 16, IVS21+2-3insT in intron
21, c.4269+1_4269+12del12bp in intron 24, 4861G>A
and 4862T>G (V1621R) in exon 28, c.5749+4_+7delAG-
TA in intron 30, c.5750-?_5943+?del in intron 31, and
c.61-?_8315-?del in intron 47.
The majority of these mutations resulted in a truncated
or shortened protein product. Only three missense mutations,
L578P, R1276Q, and V1621R, do not affect the size of neuro-
fibromin. Two mutations, c.4537 in exon 27 (patients 14
and 15 in Table 1) and c.6792 in exon 37 (patients 20 and
21 in Table 1) were each found in two patients. Two muta-
tions, R1276Q and R1513X, were detected in the GAP
related domain (GRD) which has been suggested to be a ‘‘hot
spot’’ for NF1 mutations, given its important functional role
in modulating Ras activity (14). Another two mutations,
L578P and R816X, were observed in the cAMP-dependent
protein kinase recognition sites (6).
Genotype-phenotype correlation analysis
Phenotypic characterization revealed that the only clinical
feature common to all patients was the CAL spots (Table 1).
To identify genotype-phenotype associations, we first ana-
lyzed six NF1 patients (5 sporadic cases and 1 familial case)
who share an identical phenotype, plexiform neurofibromas.
Among them, five patients (5, 7, 14, 15, and 20 in Table 1)
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Fig. 1. Location of the NF1 gene mutations detected in 22 unrelated Korean NF1 patients. The cAMP protein kinase recognition sites (cAMP/
PK) spanning exons 11-17 and the GAP related domain (GRD) region spanning exons 20-27 are highlighted.110 S.-Y. Jeong, S.-J. Park, H.J. Kim
possessed mutations which caused a splicing error (c.1642-
449A>G and c.2033_2034insC) or mutations which pro-
duced a truncated neurofibromin (R1513X and Y2264X),
but one patient (16 in Table 1) had a mutation which resulted
in an amino acid substitution (V1621R). This result indicates
that the effects of different mutations are not always distin-
guishable at the phenotypic level. Despite distinct genotypes,
the patients shared the same phenotype, plexiform neurofi-
broma, suggesting that there is no obvious correlation between
the type of mutation and the severity of the disease. 
Similarly, patients 14 and 15 carried the same nonsense
mutation (R1513X), but had no clinical features in common,
with the exception of the CAL spots. In contrast, patients
20 and 21 who possessed the same truncated neurofibromin
by mutation of Y2264X showed distinct clinical features
with the occurrence of neurofibromas and scoliosis in one
patient, and microcephaly and seizures in the other. Our data
suggest that there is no clear relationship between specific
NF1 mutations and clinical features. 
DISCUSSION
A survey of previously reported NF1 mutations listed in
the HGMD revealed that the most frequent type of mutation
is a small deletion and the next most frequent type is nucleotide
substitution. However, our data indicate that the most fre-
quent mutation type is nucleotide substitution (11 of 22
cases) and followed by splicing error mutations (10 of 21 cases).
Only one deletion mutation was identified in our study, sug-
gesting that the genotypic characteristics of Korean NF1
patients may be distinct from that of other populations. 
Only three cases of NF1 mutation in Koreans have been
previously described (11, 12). Park et al. reported two frame
shift mutations (a TGGA insertion at codon 1270 of exon
22 and a one base pair deletion at codon 1398 of exon 24)
(11) and one nonsense mutation (R1947X) (12). Recently,
another 30 Korean cases were reported at the 29th Sympo-
sium of the Korean Society of Medical Genetics (2004), by
Lee et al., Department of Clinical Genetics, College of Medi-
cine, Yonsei University, Seoul, Korea. A review of the 55
Korean NF1 genotypes available, including the above 30
cases, showed that most Korean NF1 patients bear unique
mutations, with the exception of two mutations, c.4537C>T
in exon 27 and c.6709C>T in exon 36. These data indicate
that the mutational spectrum in Korean NF1 patients is highly
variable.
Two mutations were detected in 3 patients in exons 20-
27 which correspond to the GRD of neurofibromin. The
GRD is known to be the most important functional domain
of the NF1 gene. The predicted GRD in neurofibromin con-
sists of 367 amino acids (1172-1538) and shares homology
with GAP family proteins such as p120GAP in yeast and
mammals (3). This region of the gene has also been reported
as representing a ‘‘hot spot’’ for mutations (15). The crystal
structure of the GRD of neurofibromin revealed that three
prominent regions in the GRD, the arginine-finger loop,
the phenylalanine-leucine-arginine (FLR) region, and the  7/
variable loop contain structural fingerprints governing the
GAP function of neurofibromin (4, 5). The finger loop is
crucial for stabilization of the transition state of the GTPase
reaction whose function is controlled by residues proximal
to the catalytic arginine (R1276). In the previous report,
missense mutations at R1276 in the GRD showed severe
phenotypes (16). The substitution, R1276P, was found as
an apparently spontaneous mutation in an NF1 patient with
malignant schwannona (16). The R1276P mutation slightly
reduced the binding affinity to Ras, but resulted in an 8000-
fold reduction of GAP-stimulated GTP hydrolysis (17), sug-
gesting that the loss of GAP function is critical for the devel-
opment of neurofibromatosis. In this study, however, patient
12 in Table 1, with the missense mutation R1276Q, showed
mild neurofibromas. It may be that the phenotypic variations
between the two patients are caused by the difference in the
change of the amino acid residues P and Q. 
A putative second hot spot in a possible functional domain
upstream of GRD, comprising exons 11-17, has been describ-
ed (6, 16). The region is rich in cysteine and serine, with three
cysteine pairs suggestive of ATP binding sites, as well as
three potential cAMP-dependent protein kinase recognition
sites. Two mutations, L578P and R816X, have been observed
in two of the cAMP-dependent protein kinase recognition
sites (6). Further evidence for cAMP signaling being per-
turbed in NF1 comes from mutations in Drosophila neurofi-
bromin that have been shown to inhibit the cAMP-depen-
dent protein kinase signaling pathway (6, 18). 
Many NF1 patients have been genotyped, but little evi-
dence of genotype-phenotype correlation has been observed
(19). This may indicate that the phenotypic differences result-
ing from NF1 allelic heterogeneity are generally small in
comparison to other sources of variability. It is also possible,
however, that important NF1 genotype-phenotype correla-
tions exist but have not been recognized because of the com-
plexity of the NF1 phenotype and the heterogeneity of patho-
genic NF1 mutations (13, 15, 17).
In this study, Korean NF1 patients showed a wide range
of phenotypic variations. We found that patients exhibited
different disease phenotypes, even though they carried an
identical NF1 mutant allele. Two patients (14, 15) shared
the same mutation, R1513X, but their clinical features were
substantially different. Although they shared the clinical
features of CAL spots and plexiform neurofibromas, patient
15 also showed several other NF1 clinical features including
subcutaneous plexiform neurofibromas, freckling, Lish nod-
ules, and subcutaneous neurofibromas (Table 1). R1513X is
one of the most prevalent NF1 gene mutations (20). One
patient with R1513X mutation was characterized by the
typical clinical features of CAL spots, axillary freckling, andnodular neurofibromas (14). In contrast, other patients with
the R1513X mutation had malignant myeloid disorders
(21). These data indicate that the R1513X mutation in the
NF1 gene is associated with malignant myeloid disorders as
well as NF1. Comparison of phenotypes among the patients
with R1513X mutation, in previously reported studies and
in this study, reveals that there is no correlation between
genotype and phenotype in NF1 patients.
Other common mutations, c.6792C>G and c.6792C>A,
caused an alternative splicing event which skipped exon 37
and produced a neurofibromin protein lacking 34 amino
acid residues (22). These mutations were found in patients
20 and 21, respectively. Even though these mutations result
in the same effect at the protein level, Y2264X, their pheno-
types were distinguished by the presence of plexiform neuro-
fibromas, cutaneous neurofibromas, subcutaneous neurofi-
bromas, and scoliosis in the patient 20, versus microcephaly
and seizures in the patient 21. One NF1 patient with a
Y2264X mutation was reported (23) to have symptomatic
optic glioma and multiple clinical features that do not ful-
fill the NIH criteria (7) for the clinical diagnosis of NF1,
while another patient with the same mutation was reported
to have the typical clinical features of NF1, CAL spots, axil-
lary freckling, and cutaneous neurofibromas. Analysis of the
genotype-phenotype correlation by comparison of clinical
features among the above patients and the patients in this
study suggests that phenotypic variation in NF1 patients is
not correlated with the type of mutations, as reported previ-
ously (8-10).
In conclusion, the location and type of mutation within
the NF1 gene and its putative effect at the protein level do
not indicate a relationship to any specific clinical features of
NF1, suggesting that unlinked modifying gene(s) may be
involved in the development of particular clinical features of
NF1 and that some of the clinical variability that character-
izes NF1 may result from association of more than one genetic
factor. Recently two candidate modifiers for NF1, GDNF
and TLF, have been reported (24, 25). However, there has
been no clear evidence to explain the phenotypic variations
among patients with an identical mutation.
A larger number of NF1 cases may be required to identify
potential genotype-phenotype correlations in Korean patients
with NF1. A functional analysis of NF1 gene mutations in
specific regions, such as the GRD, may clarify the mecha-
nisms of pathogenesis associated with NF1. This study will
contribute to a better understanding the genotypic and phe-
notypic characteristics of Korean NF1 patients.
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